A New Derivative of Retro-2 Displays Antiviral Activity against Respiratory Syncytial Virus.

ABSTRACT: Human respiratory syncytial virus (hRSV) is the most common cause of bronchiolitis and pneumonia in newborns, with all children being infected before the age of two. Reinfections are very common throughout life and can cause severe respiratory infections in the elderly and immunocompromised adults. Although vaccines and preventive antibodies have recently been licensed for use in specific subpopulations of patients, there is still no therapeutic treatment commonly available for these infections. Here, we investigated the potential antiviral activity of Retro-2.2, a derivative of the cellular retrograde transport inhibitor Retro-2, against hRSV. We show that Retro-2.2 inhibits hRSV replication in cell culture and impairs the ability of hRSV to form syncytia. Our results suggest that Retro-2

SUBMITTER: Le Rouzic A 

PROVIDER: S-EPMC10778932 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature